MLAB 2431 Immunohematology
 

Unit 9 Objectives: Other Blood Group Systems

  1. Define "high-incidence" or "public" and “low-incidence or "private" antige.ns
  2. Define "low-incidence", "private antigens" or "low frequency".
  3. Describe the importance of knowing the in-vitro serologic behavior and characteristics of the major blood group antibodies.
  4. State the in-vitro clinical significance of IgM antibodies which usually react at immediate spin and IgG which usually react at 37C or AHG.
  5. State the criteria for an antibody to be considered clinically significant in-vivo.
  6. For each of the following blood groups state the following: antigens, antigenic development (if important), most common antibody class produced, phase of reactivity in in-vitro testing, clinical significance, whether donors must be antigen negative, i.e., transfusion practice, and any unique characteristics of the blood group antigens and/or antibodies.

    • I/i
    • Lewis
    • P
    • MN
    • S, s and U
    • Lutheran
    • Kell
    • Duffy
    • Kidd
    • Rh

  7. List the diseases associated with anti-I and anti-i.
  8. Describe the serological testing utilized to confirm the specificity and eliminate reactivity of I/i antibodies.
  9. Describe the development of the Lewis antigens on to the red blood cells.
  10. Describe Lewis antigen and antibody activity during pregnancy.
  11. State the principle of the Lewis neutralization test.
  12. Explain how a person's secretor status influences their Lewis phenotype.
  13. Give the Lewis phenotype of a secretor and nonsecretor and state what percentage of the population are secretors.
  14. State two substances used to neutralize or inhibit anti-P1.
  15. State the principle of the P1 neutralization/inhibition test.
  16. Describe how acidifying the serum affects antibodies to M.
  17. Define "dosage affect" as it relates to antigen/antibody reactions.
  18. Name the anti-N lectin.
  19. Name the high incidence antigen which black individuals of the S-s- phenotype may also be negative for.
  20. Explain why anti-Lua does not cause HDN.
  21. Describe the characteristic agglutination reaction demonstrated by Lutheran antibodies.
  22. State the antibody class and immunogenicity of anti-Lua and anti-Lub.
  23. Describe the immunogenicity of the Kell antigen.
  24. Describe the relationship of Kpa, Kb, Jsa and Jsb with the Kell blood group system.
  25. Describe the method utilized to detect other alloantibodies when a Duffy antibody is present.
  26. State the disease from which people of the Fy (a-b-) phenotype are resistant to.
  27. State the reason fresh serum may be the specimen of choice when Kidd antibodies are suspected.
  28. Describe the dangers involved during transfusion if a Kidd antibody goes undetected.
  29. List four additional pairs of antithetical blood group system antigens which may cause production of unexpected antibodies and why these antibodies are infrequently encountered.
  30. Name the only sex linked blood group.
  31. Describe the difficulty of working up an antibody and finding blood for individuals with antibodies to high incidence antigens.
  32. Describe what is meant by HTLA antibodies and the types of problems they cause in serological testing.
  33. Describe the classic type agglutination reaction seen with Sda antibodies.
  34. State the principle of the procedure used to neutralize Sda antibodies.
  35. Explain why antibodies to low incidence antigens do not cause much of a problem .
  36. Describe the Bg antigens and the problems the antibodies cause in serological testing.

 

Last Update: February 28, 2011
Web Author: Terry Kotrla, MS, MT(ASCP)BB
Comments: kotrla@austincc.edu
Copyright ©2000 by Terry Kotrla - All Rights Reserved